Koen Ameloot, MD, PhD discussed the Neuroprotect trial, which looked at 112 survivors of out-of-hospital cardiac arrest who were unconscious at hospital admission and were randomly assigned to early goal directed hemodynamic optimization (EGDHO) – targeting a higher mean arterial blood pressure (85-100mmHg) in post-cardiac arrest patients during the first 36 hours after hospital admission – versus standard care.

Results showed that EGDHO is safe and improved cerebral perfusion and oxygenation as compared to standard care. However, it did not reduce the extent of anoxic brain damage on DW-MRI or functional outcome, the primary outcome.

The authors conclude that EGDHO clearly improved cerebral perfusion and oxygenation thereby for the first time providing the proof of concept for this therapy.